drug · small molecule
centanafadine SR
pre_registrationupdated 3mo agoby Otsuka Pharmaceutical Co Ltd🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
targets
Monoamine transporter
all catalysts(0)
nothing on the calendar yet
Trials studying centanafadine SR
- phase3A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
- phase3A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
- phase3P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
- phase1Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
- phase1A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine
- phase1A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
- phase3A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
- phase3A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
News(2)
- Otsuka’s ADHD approval opens up new drug class with $615M opportunityOtsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.biospace · 21d ago
- FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences servicesReplimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.biopharma_dive · 1mo ago
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that